Putting Pfizer after Astrazeneca: produces immune response and mild effects, according to a Carlos III study

Preliminary results of the 'CombiVacs' clinical trial, launched by the Carlos III Health Institute (ISCIII), have shown that one dose of Pfizer's COVID-19 vaccine produces a strong immune response and mild to moderate side effects. in people under 60 years of age who received a single dose of AstraZeneca.In early April, Health made the decision to vaccinate with AstraZeneca only those over 60 years of age due to the occurrence of "very rare" thrombotic events especially in younger people Following the example of other European countries such as France or Germany, this restriction meant that many under 60s who had already received a dose of AstraZeneca could not receive the required second injection. Those affected are, mainly, essential personnel such as teachers or police The trial has been carried out in five Spanish hospitals: La Paz in Madrid, the San Carlos Clinic in Madrid, the Vall d'Hebron in Barcelona, the Barcelona Clinic and the Cruces of Vizcaya. The National Center for Microbiology, for its part, has also participated as the central analysis laboratory of the study.In this phase 2, comparative, randomized and adaptive clinical trial, 676 patients of different age groups and regions of Spain have participated who have received a single dose of AstraZeneca and they range from 18 to 59 years old. They have been divided into two groups: one of 226 who received the dose "immediately" and another of 450 who received it after 28 days. The results presented this Tuesday are those analyzed 14 days after receiving the Pfizer dose. (News in expansion)